Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global DNA Gyrase Subunit B (EC 5.99.1.3) market size will reach US$ million by 2031.
United States market for DNA Gyrase Subunit B (EC 5.99.1.3) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for DNA Gyrase Subunit B (EC 5.99.1.3) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for DNA Gyrase Subunit B (EC 5.99.1.3) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key DNA Gyrase Subunit B (EC 5.99.1.3) players cover Abgentis Limited, AstraZeneca Plc, Daiichi Sankyo Company Ltd, Merck & Co., Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “DNA Gyrase Subunit B (EC 5.99.1.3) Industry Forecast” looks at past sales and reviews total world DNA Gyrase Subunit B (EC 5.99.1.3) sales in 2024, providing a comprehensive analysis by region and market sector of projected DNA Gyrase Subunit B (EC 5.99.1.3) sales for 2025 through 2031. With DNA Gyrase Subunit B (EC 5.99.1.3) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world DNA Gyrase Subunit B (EC 5.99.1.3) industry.
This Insight Report provides a comprehensive analysis of the global DNA Gyrase Subunit B (EC 5.99.1.3) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on DNA Gyrase Subunit B (EC 5.99.1.3) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global DNA Gyrase Subunit B (EC 5.99.1.3) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for DNA Gyrase Subunit B (EC 5.99.1.3) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global DNA Gyrase Subunit B (EC 5.99.1.3).
This report presents a comprehensive overview, market shares, and growth opportunities of DNA Gyrase Subunit B (EC 5.99.1.3) market by product type, application, key players and key regions and countries.
Segmentation by Type:
GYR-12
DS-2969
VXC-100
VT-12008911
Others
Segmentation by Application:
Bacterial Infections
Clostridium Diffclie Infections
Klebsiella Pneumoniae Infections
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abgentis Limited
AstraZeneca Plc
Daiichi Sankyo Company Ltd
Merck & Co., Inc.
Please note: The report will take approximately 2 business days to prepare and deliver.
United States market for DNA Gyrase Subunit B (EC 5.99.1.3) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for DNA Gyrase Subunit B (EC 5.99.1.3) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for DNA Gyrase Subunit B (EC 5.99.1.3) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key DNA Gyrase Subunit B (EC 5.99.1.3) players cover Abgentis Limited, AstraZeneca Plc, Daiichi Sankyo Company Ltd, Merck & Co., Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “DNA Gyrase Subunit B (EC 5.99.1.3) Industry Forecast” looks at past sales and reviews total world DNA Gyrase Subunit B (EC 5.99.1.3) sales in 2024, providing a comprehensive analysis by region and market sector of projected DNA Gyrase Subunit B (EC 5.99.1.3) sales for 2025 through 2031. With DNA Gyrase Subunit B (EC 5.99.1.3) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world DNA Gyrase Subunit B (EC 5.99.1.3) industry.
This Insight Report provides a comprehensive analysis of the global DNA Gyrase Subunit B (EC 5.99.1.3) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on DNA Gyrase Subunit B (EC 5.99.1.3) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global DNA Gyrase Subunit B (EC 5.99.1.3) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for DNA Gyrase Subunit B (EC 5.99.1.3) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global DNA Gyrase Subunit B (EC 5.99.1.3).
This report presents a comprehensive overview, market shares, and growth opportunities of DNA Gyrase Subunit B (EC 5.99.1.3) market by product type, application, key players and key regions and countries.
Segmentation by Type:
GYR-12
DS-2969
VXC-100
VT-12008911
Others
Segmentation by Application:
Bacterial Infections
Clostridium Diffclie Infections
Klebsiella Pneumoniae Infections
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abgentis Limited
AstraZeneca Plc
Daiichi Sankyo Company Ltd
Merck & Co., Inc.
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
80 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 DNA Gyrase Subunit B (EC 5.99.1.3) Market Size by Player
- 4 DNA Gyrase Subunit B (EC 5.99.1.3) by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

